Arash Rezazadeh Kalebasty

13PUBLICATIONS
82CO-AUTHORS
Pharmaceutical delivery technologiesMolecular targetsEpigenetics (incl. genome methylation and epigenomics)Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 09, 2026
Phase I/II Study of Bavdegalutamide, a Proteolysis-Targeting Chimera Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer.

|Sep 24, 2026
Comparative Pharmacovigilance Analysis of Safety Signals Among Advanced Prostate Cancer Therapies Using FAERS (FDA Adverse Event Reporting System).

|Aug 07, 2025
Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper Tract and Bladder Urothelial Carcinoma.

Kit Yuen, Margaret Meagher, Jacob Mercer

|Jul 29, 2025
Genes Encoding Multiple Modulators of the Immune Response Are Methylated in the Prostate Tumor Microenvironment of African Americans.

Vinay Kumar, Tara Sinta Kartika Jennings, Lucas Ueta

|Oct 16, 2024
The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond.

Farshad Sheybaee Moghaddam, Sami Dwabe, Nataliya Mar

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

Pageof 3

Frequent Collaborators

5 joint publications

Cora N Sternberg

4 joint publications

Petros Grivas

4 joint publications

Daniel P Petrylak

3 joint publications

Scott T Tagawa